Lexeo Therapeutics Secures $95 Million in Equity Financing, Extends Runway to 2027
Lexeo Therapeutics announced an oversubscribed $95.0 million equity financing, extending their financial runway into 2027 with a private placement co-led by Braidwell LP and Adage Capital Partners LP.This financing round also saw participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, and Novo Holdings A/S.
This significant investment will undoubtedly bolster Lexeo’s ability to advance their pipeline of groundbreaking therapies and drive innovation in the rare disease space.The participation of reputable investors further validates the potential of Lexeo’s platform and signals confidence in the company’s future prospects.
As of now, Lexeo Therapeutics Inc has 1.626734 million shares outstanding, with a current price of $15.13.With the infusion of $95 million in equity financing, investors can expect increased momentum and potentially positive movement in the company’s shares as Lexeo continues to make strides in advancing their therapeutic programs.
Overall, this latest financing round signifies a vote of confidence in Lexeo’s vision and capabilities, positioning the company for growth and success in the years to come.
Comments